Project Grant R42HD097831
- Acatechol, Inc. was awarded a $274,982 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to develop an innovative anti-infective coating for Foley catheters. The project aims to create a hybrid coating that combines biofilm-repellent and antimicrobial properties to provide prolonged resistance against pathogen colonization and catheter-associated urinary tract infections (CAUTIs). This work is being conducted under the NSF Technology, Innovation, and...
- Federal Grant Award Summary Cutcath LLC received a $395,306 Small Business Technology Transfer (STTR) Phase I project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for December 31, 2026. The company is developing and testing the Cutcath Dissection Septum Cutting Catheter (DSCC), a novel minimally invasive electrosurgical device designed to address acute aortic...
- This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is focused on the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by reducing or eliminating them through the use of this biocompatible and antimicrobial nano-biological coating. The $305,000...
- This $550,000 Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a remote monitoring system to reduce infections among patients undergoing peritoneal dialysis (PD). The project aims to enable real-time, continuous, and quantitative monitoring of biomarkers in dialysate to facilitate early detection and diagnosis of PD-associated infections. To achieve this, the project team will:...
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $275,000 to Carrtech Corp, a woman-owned small business manufacturer, to develop an integrated, single-needle filter system to remove glass shards from injectable fluids. The project aims to create a novel, disposable, inline mechanical filter that addresses the current multi-step process healthcare providers must use to filter glass ampoules prior to injection,...
- Federal Cooperative Agreement Award Summary Promedix, Inc. received a $1.14M Small Business Innovation Research (SBIR) Phase II cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), effective September 1, 2025 through August 31, 2027. The company is developing an automated electronic measurement device that quantifies capillary refill time to accelerate sepsis diagnosis and treatment in clinical settings. The device...
- The National Science Foundation awarded a $255,957 STTR Phase I Project Grant to CHS Healthcare Ventures Inc., doing business as Lightengale, to develop a lighted infusion line to optimize care and decrease complications for critically ill patients in infectious isolation situations such as COVID-19. The grant is funded through the NSF's Technology, Innovation, and Partnerships program (CFDA 47.084) and aims to advance science and engineering research leading to breakthrough technologies and...
- Federal Project Grant Award Summary Nimble Surgical Incorporated received a $314,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of September 14, 2026. The company will develop and advance the FLEXLOCK guide catheter, an innovative manually-operable device featuring an anchoring tip designed to provide simultaneous active and passive support...
- Federal Grant Award Summary Dogpatch Medical LLC received a $306,463 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective September 1, 2025, through August 31, 2026. The award supports development of PassiveCAth, an innovative microcatheter device designed to enhance intra-arterial (IA) drug delivery to the central nervous...
SNAPCAP: A DEVICE TO DECONTAMINATE CENTRAL VENOUS CATHETERS (CVC) WITH 5 SNAPS - PROJECT SUMMARY/ABSTRACT WE PROPOSE A NEW APPROACH TO THE DECONTAMINATION OF CENTRAL VENOUS CATHETERS AND THE PREVENTION OF CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTIONS (CLABSI), AN IMPORTANT HEALTHCARE-ASSOCIATED INFECTION. CLABSIS COST THE US HEALTHCARE SYSTEM APPROXIMATELY $2.3 BILLION ANNUALLY (PRONOVOST, NEJM, 2009). ADDITIONALLY, CLABSIS CAN BE LIFE THREATENING, ESPECIALLY IN THE VERY YOUNG AND CRITICALLY ILL. EVEN WHEN TREATED APPROPRIATELY, THEY CAN RESULT IN ENDOCARDITIS, MENINGITIS, BONE AND JOINT INFECTIONS. CURRENT GUIDELINES TO CLABSI PREVENTION INCLUDE A KEY RECOMMENDATION TO DECONTAMINATE THE CENTRAL VENOUS CATHETER (CVC) BY SCRUBBING FOR 15 SECONDS USING A 70% ISOPROPYL ALCOHOL PAD PRIOR TO EACH USE (E.G. ADMINISTRATION OF AN INTRAVENOUS MEDICATION). IN BUSY WORKFLOWS (E.G. THE INTENSIVE CARE UNIT), COMPLIANCE WITH THESE RECOMMENDATIONS IS INCONSISTENT. SNAPCAP IS A DISPOSABLE DEVICE THAT HOUSES A COMPRESSIBLE ALCOHOL-SOAKED FOAM BETWEEN NON-CIRCUMFERENTIAL FEMALE LUER THREADS INSIDE OF A PLASTIC HOUSING. TO DECONTAMINATE A NC, A PROVIDER ENGAGES THE SNAPCAP THREADS ONTO THE NC AND TURNS IT 5 TIMES, EACH TIME SENSING AN AUDIBLE AND TANGIBLE CLICK, AS WELL AS THE SQUEEGEE SOUND OF THE NC AGAINST THE CLEANSING ALCOHOL-SOAKED SPONGE. THIS DECONTAMINATION PROCESS CHANGES THE FOCUS FROM THE CLOCK TO THE PATIENT, IS FAST (~3 SECONDS), IS EASY TO PERFORM AND CONSISTENTLY APPLIES A GREATER FORCE TO THE FACE OF THE NC THAN MANUAL SCRUBBING. IN OUR PHASE I WORK, WE DEMONSTRATED THAT SNAPCAP USE PRODUCES AN EQUIVALENT REDUCTION IN BACTERIAL LOAD AS A 15 SECOND MANUAL SCRUB. WE ALSO DEMONSTRATED THAT SNAPCAP IMPROVES COMPLIANCE WITH CLEANING STANDARDS FROM 8% (=15 SECOND SCRUB WITH ALCOHOL SWAB) TO 87% (=5 SNAPCAP SNAPS) IN A SIMULATED ENVIRONMENT. WE PROPOSE THE FOLLOWING AIMS TO TRANSITION TO COMMERCIALIZATION. AIM 1. TO ESTABLISH MANUFACTURABILITY OF SNAPCAP IN THE SETTING OF A LOW VOLUME R & D PRODUCTION LINE. AIM 2. TO COMPLETE GOOD LABORATORY PRACTICE (GLP) EFFICACY TESTING AND SEAL AND PEEL TESTING OF FINAL-DESIGN SNAPCAP PRODUCT, AND TO OBTAIN FDA APPROVAL VIA 510K REGULATORY PATHWAY. AIM 3. TO ASSESS THE USABILITY OF SNAPCAP IN ACTIVE CLINICAL ENVIRONMENTS, QUANTIFYING FREQUENCY OF ADOPTION, ITS IMPACT ON COMPLIANCE WITH CLEANING MEASURES, AND OBTAINING END-USER DESIGN FEEDBACK. IF SUCCESSFUL, THIS WORK WOULD RESULT IN NEAR-TERM COMMERCIALIZATION OF SNAPCAP AND WOULD CREATE A COMPLEMENTARY, EFFICIENT, EFFECTIVE DEVICE TO IMPROVE COMPLIANCE WITH CLEANING RECOMMENDATIONS. DUE TO THE IMPORTANCE OF CVC DECONTAMINATION IN CLABSI PREVENTION, THIS DEVICE MAY DECREASE THE INCIDENCE OF CLABSI AND REDUCE HEALTHCARE COSTS. FOLLOWING A SUCCESSFUL PHASE II EFFORT, WE PRESENT KEY COLLABORATIONS AND FUNDING TO ESTABLISH FULL-SCALE MANUFACTURING, MARKETING, DISTRIBUTION AND CLINICAL ADOPTION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 2/27/24 | ||
| Not listed | $0 | 7/29/22 | ||
| Not listed | $0 | 7/29/22 | ||
| Not listed | $0 | 6/29/22 | ||
| Not listed | $0 | 6/29/22 |